Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer

Kurume Medical Journal

Volumn 48, Issue 2, 2001, Pages 93-98

  Araki, Yasumi ^a   Isomoto, Hiroharu ^b   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

5 FU sensitivity; Colorectal cancer; Dihydropyrimidine dehydrogenase; Thymidylate synthase

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CARBON 14; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; RALTITREXED; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RADIOENZYMATIC ASSAY;

EID: 0034859473     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.48.93     Document Type: Article

References (32)

1. Heiderberger C, Chaudhuri NK, and Duschinsky R. Fluorinated pyrimidines: a new class of tumor-inhibitory compounds. Naturel957; 179:663-666.
2. Johnson PWM, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991; 64:603-605.
3. Diasio RB, and Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16:215-237.
4. Parker WB, and Cheng YC. Metabolism and mechanism of action of 5-fluouracil. Pharm Ther 1990; 48:381-395.
5. Danenberg PV. Thymidylate synthetase a target enzyme in cancer chemo-therapy. Biochem Biophys Acta 1977; 473:73-92.
6. Hartman KY, and Heidelberger C. Studies on fluorinated pyrimidines, VDI. Inhibition of thymidylate synthase. J Biol Chem 1961; 236:3006-3018.
7. Langenback RJ, Darnenberg PV, and Heidelberger C. Thymidylate synthase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate. Biochem Biophys Res Commun 1972; 48:1565-1571.
8. Spears CD, Shahinian AH, Moran RG, Heidelberger C, and Corbett TH. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res 1982; 43:450-456.
9. Spears CD, Gustavsson BG, Berne M, Frosing R, Bernstein L et al. Mechanism of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988; 48:5894-5900.
10. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-2647.
11. Peters GJ, van der Wolt CL, Groeningen CJ, Smid K, Meijer S et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: complications for treatment with fluorouracil. J Clin Oncol 1994; 12:2035-2042.
12. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412.
13. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 4:176-182.
14. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsh A, Gusterson BA et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997; 15:1923-1931.
15. Leichma CG, Lenz HJ, Leichman L, Danenberg K, Baranda J et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-3229.
16. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi C et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastasis predicts for clinical outcome of fluorouracil-based chemotherapy. J Clin Oncol 1990; 17:1760-1770.
17. Naguib FMN, Kouni MH, and Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45:5405-5412.
18. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91:105-112.
19. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S et al. Colorectal tumors responding to 5-fluouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
20. Etinne MC, Cheradame S, Fischel JL, Formento P, Dassonville O et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13:1633-1670.
21. McMurrough J, and McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996; 41:425-427.
22. Koezuka M, Kondo N, Kobayashi H, Hara S, and Yasutomi M. Drug sensitivity test for primary culture of human cancer cells using collagen gel embedded culture and image analysis. Int J Oncol 1993; 2:953-959.
23. Kobayashi H, Tanisaka K, Kondo N, Mito Y, and Koezuka M. Development of new in vitro chemosensitivity test using collagen-gel droplet embedded culture and its clinical usefulness. Jpn J Cancer Chemothe 1995; 22:1933-1939.
24. Lawler EM, Miller FR, and Heppner GH. Significance of three-dimensional growth patterns of mammary tissues in collagen gels. In Vitro 1983; 19:600-610.
25. Yang J, and Nandi S. Growth of cultured cells using collagen as substrate. Int Rev Cytol 1983; 81:249-286.
26. Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M et al. An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J 1999; 46:163-166.
27. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30:1517-1522.
28. Germ J, Danenberg K, Behan K, Parr A, Young L et al. Thymidine kinase, thymidylate synthase, dihydropyrimidine dehydrogenase & p53 profiles of cell lines in the National Cancer Institute anticancer drug screen. Am Asso Cancer Res 1999; 40:8.
29. Saltz L, Danenberg K, Paty P, Kelsen D, Kemeny N et al. High thymidylate synthase expression does not pre-clude activity of CPT-11 in colorectal cancer. Proc Am Soc Clin Oncol 1998; 17:28.
30. Young A, Topham C, and Moore J. A patient preference study comparing raltitrexed (Tomudex) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side effects and administration attributes. Eur J Cancer Care 1999; 8:154-161.
31. Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP et al. Phase I and pharmacologic study of oral fluouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000; 18:915-926.
32. Ahmed FY, Johnston SJ, Cassidy J, O'Kelly T, Binnie N et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 1999; 17:2439-2445.